Myriad Genetics to Host Investor Event on October 9, 2024
Myriad Genetics (NASDAQ: MYGN) has announced an Investor Event scheduled for October 9, 2024, at the Westin Grand Central Hotel in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) has announced an Investor Event scheduled for October 9, 2024, at the Westin Grand Central Hotel in New York City. The event, starting at 9:00 am EDT, will last approximately two hours and feature presentations from CEO Paul J. Diaz and other executive leaders.
Topics to be discussed include:
- Long-term growth strategy
- Operational initiatives
- Scientific and clinical advancements in the product pipeline
- Long-term financial goals
In-person attendance requires registration, while a live webcast will be available on Myriad's investor relations website. A replay will be accessible for at least 30 days following the event.
Details
News Market Reaction – MYGN
The recorded move for MYGN in the trading session of this news was +9.07%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Event at the Westin Grand Central Hotel in New York City on October 9, 2024. The in-person event will commence at 9:00 am EDT and last approximately two hours.
Paul J. Diaz, President and CEO, and other members of the Myriad executive leadership team will discuss the company’s long-term growth strategy, operational initiatives, scientific and clinical advancements reflected in its product pipeline, and long-term financial goals.
For those interested in attending the event in person, please register here. For those unable to attend in person, a live webcast of the Investor Event presentation and Q&A will be available on Myriad’s investor relations website at investor.myriad.com. A replay will be posted on Myriad Genetics’ website after the event and will be available for at least 30 days following.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.